NCT Number: NCT06029998
Phase: PHASE2
Trial Summary: The goal of this clinical trial is to test the anti-tumor activity of bortezomib in participants with Metastatic Castration Resistant Prostate Cancer (mCRPC) with PTEN Deletion.
The main question[s – see clinicaltrials.gov for information and location
Clinicaltrials.gov
Trial Sponsor(s): University of Utah
Acronym: BORXPTEN